Rare Disease Advisor/LinkedIn
Oct 9, 2026, 10:53
Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
Rare Disease Advisor shared a post on LinkedIn:
“New article posted on Rare Disease Advisor: “Switching From Emicizumab to Denecimig Seems Well Tolerated in Hemophilia A.’
Read the full article here.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT
-
Oct 9, 2026, 07:00Danny Reardon: Closing the Global Awareness Gap on Blood Clots